HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Mankind Pharma Ltd Stock Comparison

Alivus Life Sciences Ltd vs Mankind Pharma Ltd Stock Comparison

Last Updated on: Aug 14, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 953.55 as of 14 Aug 15:30.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 50.2 on March 2025 . This represents a CAGR of 2.16% over 2 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 99973 crore on March 2025 . This represents a CAGR of 4.23% over 2 years.
  • The revenue of Alivus Life Sciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Mankind Pharma Ltd for the Jun '25 is ₹ 3653 crore as compare to the Mar '25 revenue of ₹ 3333 crore. This represent the growth of 9.61%.
  • The ebitda of Alivus Life Sciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Mankind Pharma Ltd for the Jun '25 is ₹ 929.82 crore as compare to the Mar '25 ebitda of ₹ 932.5 crore. This represent the decline of -0.29%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Mankind Pharma Ltd changed from ₹ 494.19 crore to ₹ 444.62 crore over 9 quarters. This represents a CAGR of -4.59% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Mankind Pharma Ltd changed from 31.56 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Mankind Pharma Ltd

  • Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
  • Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
  • It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

Alivus Life Sciences Ltd News Hub

News

Alivus Life Sciences to conduct AGM

Alivus Life Sciences announced that the Annual General Meeting(AGM) of the company will be...

Read more

12 Aug 2025 12:09

News

Alivus Life Sciences to declare Quarterly Results

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 1 Aug...

Read more

25 Jul 2025 11:06

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

Mankind Pharma Ltd News Hub

News

Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs ...

Read more

11 Aug 2025 13:35

News

Board of Mankind Pharma recommends Interim Dividend

Mankind Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

31 Jul 2025 17:41

News

Mankind Pharma to convene board meeting

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 31 July 202...

Read more

15 Jul 2025 10:48

News

Mankind Pharma Ltd spurts 2.92%, gains for five straight sessions

Mankind Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 265...

Read more

14 Jul 2025 13:00

News

Mankind Pharma AGM scheduled

Mankind Pharma announced that the 34th Annual General Meeting(AGM) of the company will be ...

Read more

04 Jul 2025 16:31

News

Mankind Pharma allots 57,709 equity shares under ESOP

Mankind Pharma has allotted 57,709 equity shares of face value of Re. 1/- each of the Comp...

Read more

10 Jun 2025 13:26

SWOT Analysis Of Mankind Pharma Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Mankind Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Mankind Pharma Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Mankind Pharma Ltd?

Market cap of Alivus Life Sciences Ltd is 11,693 Cr while Market cap of Mankind Pharma Ltd is 102,043 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Mankind Pharma Ltd?

The stock performance of Alivus Life Sciences Ltd and Mankind Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Mankind Pharma Ltd?

As of August 14, 2025, the Alivus Life Sciences Ltd stock price is INR ₹953.55. On the other hand, Mankind Pharma Ltd stock price is INR ₹2472.4.

How do dividend payouts of Alivus Life Sciences Ltd and Mankind Pharma Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Mankind Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions